# Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects

> **NCT05491460** · PHASE1 · UNKNOWN · sponsor: **Doasense GmbH** · enrollment: 24 (estimated)

## Conditions studied

- Anticoagulant Therapy

## Interventions

- **DRUG:** Apixaban 5 MG Tab
- **DRUG:** Dabigatran 150 MG Tab
- **DRUG:** Edoxaban 60Mg Tab
- **DRUG:** Rivaroxaban 20 MG Tab

## Key facts

- **NCT ID:** NCT05491460
- **Lead sponsor:** Doasense GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2022-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05491460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05491460, "Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05491460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*